Research Papers

25 of 502 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos…
Auliac JB; Thomas PA; Bylicki O; Guisier F; Curcio H; AlainVegnenègre; Swalduz A; Wislez M; Le Treut J; Decroisette C; Basse V; Falchero L; De Chabot G; Moreau D; Huchot E; Lupo Mansuet A; Blons H; Chouaïd C; Greillier L.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis.
Petrelli F; Antista M; Marra F; Cribiu' FM; Rampulla V; Pietrantonio F; Dottorini L; Ghidini M; Luciani A; Zaniboni A; Tomasello G.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patient…
Yu N; Huang S; Zhang Z; Huang M; Wang Y; Zhang W; Zhang X; Zhu X; Sheng X; Yu K; Chen Z; Guo W.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Multivariate prognostic index and triplet regimen efficacy predictive index in locally advanced and metastatic gastric …
Feng WJ; Zhao XY; He YF; Huang MZ; Chen ZY; Wang YS; Zhu XD; Guo WJ.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-ana…
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil the…
Okunaka M; Kotani D; Fujiwara H; Sato K; Fujiwara N; Mishima S; Sakashita S; Yoshino T; Fujita T; Kojima T.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prognostic value of lymph node-to-primary tumor ratio of PET standardized uptake value for nasopharyngeal carcinoma: a …
Kong FF; Pan GS; Ni MS; Du CR; Hu CS; Ying HM.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after ne…
Liu B; Luo H; Li B; Yu H; Sun R; Li J; Gao Y; Ding P; Wang X; Xiao W; Xiao W.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ogata T; Narita Y; Oze I; Kumanishi R; Nakazawa T; Matsubara Y; Kodama H; Nakata A; Honda K; Masuishi T; Bando H; Taniguchi H; Kadowaki S; Ando M; Ito S; Tajika M; Muro K.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma.
Martin-Broto J; Olarte-García A; Fernandéz-Rodríguez R; Ferreira MR; Carrasco-García I; Galvez-Montosa F; Rincon-Perez I; Peinado-Serrano J; Azinovic I; Guzman-Gomez L; Salgado L; Sevillano A; Ortega J; Alvarez C; Gutierrez A; Moura DS; Hindi N.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene…
Ozawa Y; Koh Y; Hase T; Chibana K; Kaira K; Okishio K; Ichihara E; Murakami S; Shimokawa M; Yamamoto N.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal canc…
Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC …
Sepe P; Procopio G; Pircher CC; Basso U; Caffo O; Cappelletti V; Claps M; De Giorgi U; Fratino L; Guadalupi V; Miodini P; De Marco C; Perrucci B; Mennitto A; Santini D; Spina F; Stellato M; de Braud F; Verzoni E.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.
Tung PH; Chiu TH; Huang AC; Ju JS; Huang CH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study.
Chang CH; Huang SH; Huang HY; Lin MH; Lee CS; Lee HF; Hsieh JC; Cheng CY.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment …
Choi JH; Park H; Park JK; Lee JK; Lee KT; Lee KH.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals.
Zheng-Lin B; Bekaii-Saab TS.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
The impact of the HER2-low status on conditional survival in patients with breast cancer.
Ma T; Liu C; Ma T; Sun X; Cui J; Wang L; Mao Y; Wang H.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.
Chiong E; Saad M; Hamid ARAH; Ong-Cornel AB; Lojanapiwat B; Pripatnanont C; Serrano D; Songco J; Sin LC; Hakim L; Chua MLK; Nguyen NP; Phuong PC; Patnaik RS; Umbas R; Kanesvaran R.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors…
Burcher KM; Bloomer CH; Gavrila E; Kalada JM; Chang MJ; Gebeyehu RR; Song AH; Khoury LM; Lycan TW; Kinney R; D'Agostino R; Bunch PM; Shukla K; Triozzi P; Furdui CM; Zhang W; Porosnicu M.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poo…
Cui J; Yu T; Lv R; Liu J; Fan H; Yan W; Xu J; Du C; Deng S; Sui W; Ho M; Xu Y; Anderson KC; Dong X; Qiu L; An G.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and syn…
Zafar S; Shehzadi R; Dawood H; Maqbool M; Sarfraz A; Sarfraz Z.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Clinical and molecular characteristics of <i>RNF43</i> mutations as promising prognostic biomarkers in colorectal cance…
Huang ZY; Wen L; Ye LF; Lu YT; Pat Fong W; Zhang RJ; Wu SX; Chen ZG; Cai YY; Xu RH; Li YH; Du ZM; Wang DS.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
Liang Y; Liu X; Yun Z; Li K; Li H.
Ther Adv Med Oncol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study.
Xue J; Xue L; Tang W; Ge X; Zhao W; Li Q; Peng W; Dai C; Guo Y; Li J.
Ther Adv Med Oncol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared